Guselkumab for moderate-to-severe inflammatory bowel disease in Italy
Part of Digestive system clinical trials.
This study looks at how well guselkumab (Tremfya) works for people with moderate-to-severe Crohn's disease or ulcerative colitis in everyday medical practice in Italy. If you qualify, you will receive the treatment normally prescribed by your doctor and help researchers track its real-world effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of moderate-to-severe Crohn's disease or ulcerative colitis.
- Your doctor has decided to start you on guselkumab as part of your regular care.
- You have not been on certain other similar drugs (IL-23 inhibitors) before, except ustekinumab (Stelara) is okay.
- You have not had more than 4 different advanced treatments (biologics or small molecules) for your IBD.
- You are able to give informed consent and fill out questionnaires and a diary.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study follows adults with moderate-to-severe Crohn's disease or ulcerative colitis who are starting treatment with guselkumab (Tremfya). It aims to see how well the medication works and how long the effects last over time.
This study looks at how well guselkumab (Tremfya), a treatment for Crohn's disease and ulcerative colitis, works in everyday patients. Researchers will review medical records to see how long people stay on the medicine and how it helps their symptoms.
Hear when a new Colitis, Ulcerative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.